Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse

Luciano Giacomelli, Walter Gianni, Cristiano Belfiore, Orietta Gandini, Lazzaro Repetto, Angelo Filippini, Luigi Frati, Anna Maria Aglianò, Paola Gazzaniga

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose: Despite the great number of studies performed to detect circulating markers of disease progression in colorectal cancer, few have shown a clinical use; among those, epidermal growth factor receptor (EGFR) and, more recently, interleukin (IL)-10. In this article, we sought to investigate how primary surgery could affect expression levels of EGFR, IL-6, and IL-10 in blood from colorectal cancer patients. Experimental Design: We investigated by reverse transcriptase-PCR assay the expression at mRNA level of EGFR, IL-6, and IL-10 in blood samples taken from 56 colorectal cancer patients. Each gene expression was evaluated 1 day before and 20 days after primary surgery. Persistence of each gene in blood after surgery was then correlated to the relapse free time in a follow-up of 3 years. Results: In blood samples taken before surgery, EGFR, IL-6, and IL-10 were found expressed in 62, 100, and 100% of patients, respectively. EGFR expression, but not IL-6 and IL-10, correlates with stage of disease. In the group of 41 patients who underwent follow-up studies, EGFR was found persistently high in 67%; 94% of them had relapse. Persistence of IL-10 after surgery also identifies relapses in 89% of cases. IL-6 persistence was not found to significantly correlate to progression of disease. Conclusions: Persistence of both EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high propensity to relapse. These findings may suggest a clinical use of preoperative EGFR/IL-10 reverse transcriptase-PCR assay in the prediction of tumor recurrence.

Original languageEnglish
Pages (from-to)2678-2682
Number of pages5
JournalClinical Cancer Research
Volume9
Issue number7
Publication statusPublished - Jul 1 2003

Fingerprint

Epidermal Growth Factor Receptor
Interleukin-10
Colorectal Neoplasms
Recurrence
Interleukin-6
Reverse Transcriptase Polymerase Chain Reaction
Disease Progression
Research Design
Gene Expression
Messenger RNA
Genes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Giacomelli, L., Gianni, W., Belfiore, C., Gandini, O., Repetto, L., Filippini, A., ... Gazzaniga, P. (2003). Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. Clinical Cancer Research, 9(7), 2678-2682.

Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. / Giacomelli, Luciano; Gianni, Walter; Belfiore, Cristiano; Gandini, Orietta; Repetto, Lazzaro; Filippini, Angelo; Frati, Luigi; Aglianò, Anna Maria; Gazzaniga, Paola.

In: Clinical Cancer Research, Vol. 9, No. 7, 01.07.2003, p. 2678-2682.

Research output: Contribution to journalArticle

Giacomelli, L, Gianni, W, Belfiore, C, Gandini, O, Repetto, L, Filippini, A, Frati, L, Aglianò, AM & Gazzaniga, P 2003, 'Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse', Clinical Cancer Research, vol. 9, no. 7, pp. 2678-2682.
Giacomelli, Luciano ; Gianni, Walter ; Belfiore, Cristiano ; Gandini, Orietta ; Repetto, Lazzaro ; Filippini, Angelo ; Frati, Luigi ; Aglianò, Anna Maria ; Gazzaniga, Paola. / Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 7. pp. 2678-2682.
@article{184284177e524b04be7c23d438823685,
title = "Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse",
abstract = "Purpose: Despite the great number of studies performed to detect circulating markers of disease progression in colorectal cancer, few have shown a clinical use; among those, epidermal growth factor receptor (EGFR) and, more recently, interleukin (IL)-10. In this article, we sought to investigate how primary surgery could affect expression levels of EGFR, IL-6, and IL-10 in blood from colorectal cancer patients. Experimental Design: We investigated by reverse transcriptase-PCR assay the expression at mRNA level of EGFR, IL-6, and IL-10 in blood samples taken from 56 colorectal cancer patients. Each gene expression was evaluated 1 day before and 20 days after primary surgery. Persistence of each gene in blood after surgery was then correlated to the relapse free time in a follow-up of 3 years. Results: In blood samples taken before surgery, EGFR, IL-6, and IL-10 were found expressed in 62, 100, and 100{\%} of patients, respectively. EGFR expression, but not IL-6 and IL-10, correlates with stage of disease. In the group of 41 patients who underwent follow-up studies, EGFR was found persistently high in 67{\%}; 94{\%} of them had relapse. Persistence of IL-10 after surgery also identifies relapses in 89{\%} of cases. IL-6 persistence was not found to significantly correlate to progression of disease. Conclusions: Persistence of both EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high propensity to relapse. These findings may suggest a clinical use of preoperative EGFR/IL-10 reverse transcriptase-PCR assay in the prediction of tumor recurrence.",
author = "Luciano Giacomelli and Walter Gianni and Cristiano Belfiore and Orietta Gandini and Lazzaro Repetto and Angelo Filippini and Luigi Frati and Aglian{\`o}, {Anna Maria} and Paola Gazzaniga",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "9",
pages = "2678--2682",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Persistence of epidermal growth factor receptor and interleukin 10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse

AU - Giacomelli, Luciano

AU - Gianni, Walter

AU - Belfiore, Cristiano

AU - Gandini, Orietta

AU - Repetto, Lazzaro

AU - Filippini, Angelo

AU - Frati, Luigi

AU - Aglianò, Anna Maria

AU - Gazzaniga, Paola

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Purpose: Despite the great number of studies performed to detect circulating markers of disease progression in colorectal cancer, few have shown a clinical use; among those, epidermal growth factor receptor (EGFR) and, more recently, interleukin (IL)-10. In this article, we sought to investigate how primary surgery could affect expression levels of EGFR, IL-6, and IL-10 in blood from colorectal cancer patients. Experimental Design: We investigated by reverse transcriptase-PCR assay the expression at mRNA level of EGFR, IL-6, and IL-10 in blood samples taken from 56 colorectal cancer patients. Each gene expression was evaluated 1 day before and 20 days after primary surgery. Persistence of each gene in blood after surgery was then correlated to the relapse free time in a follow-up of 3 years. Results: In blood samples taken before surgery, EGFR, IL-6, and IL-10 were found expressed in 62, 100, and 100% of patients, respectively. EGFR expression, but not IL-6 and IL-10, correlates with stage of disease. In the group of 41 patients who underwent follow-up studies, EGFR was found persistently high in 67%; 94% of them had relapse. Persistence of IL-10 after surgery also identifies relapses in 89% of cases. IL-6 persistence was not found to significantly correlate to progression of disease. Conclusions: Persistence of both EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high propensity to relapse. These findings may suggest a clinical use of preoperative EGFR/IL-10 reverse transcriptase-PCR assay in the prediction of tumor recurrence.

AB - Purpose: Despite the great number of studies performed to detect circulating markers of disease progression in colorectal cancer, few have shown a clinical use; among those, epidermal growth factor receptor (EGFR) and, more recently, interleukin (IL)-10. In this article, we sought to investigate how primary surgery could affect expression levels of EGFR, IL-6, and IL-10 in blood from colorectal cancer patients. Experimental Design: We investigated by reverse transcriptase-PCR assay the expression at mRNA level of EGFR, IL-6, and IL-10 in blood samples taken from 56 colorectal cancer patients. Each gene expression was evaluated 1 day before and 20 days after primary surgery. Persistence of each gene in blood after surgery was then correlated to the relapse free time in a follow-up of 3 years. Results: In blood samples taken before surgery, EGFR, IL-6, and IL-10 were found expressed in 62, 100, and 100% of patients, respectively. EGFR expression, but not IL-6 and IL-10, correlates with stage of disease. In the group of 41 patients who underwent follow-up studies, EGFR was found persistently high in 67%; 94% of them had relapse. Persistence of IL-10 after surgery also identifies relapses in 89% of cases. IL-6 persistence was not found to significantly correlate to progression of disease. Conclusions: Persistence of both EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high propensity to relapse. These findings may suggest a clinical use of preoperative EGFR/IL-10 reverse transcriptase-PCR assay in the prediction of tumor recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0038493554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038493554&partnerID=8YFLogxK

M3 - Article

C2 - 12855647

AN - SCOPUS:0038493554

VL - 9

SP - 2678

EP - 2682

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -